Voltammetric evidence in vivo of cholinergic modulation of extracellular ascorbic acid and uric acid in rat striatum.
The cholinergic agonist pilocarpine (2 and 4 mg/kg) produced a dose-related increase in striatal AA levels as measured by linear sweep voltammetry. The cholinergic antagonist scopolamine (0.5 and 0.6 mg/kg) blocked the pilocarpine-induced increase in AA levels, but methscopolamine (which does not cross the blood-brain barrier) reduced the pilocarpine effect only by about 20%. Pilocarpine alone had little effect on UA levels. Scopolamine (0.6 mg/kg) produced a dramatic increase in UA levels that was reduced by pilocarpine. Methscopolamine had little effect (less than 10%) on extracellular UA levels. Thus cholinergic drugs modulate striatal extracellular AA levels by predominantly central rather than peripheral effects.
D000818:Animals; D001205:Ascorbic Acid / Q000378:metabolism*; D002799:Cholinergic Fibers / Q000187:drug effects / Q000502:physiology*; D003342:Corpus Striatum / Q000378:metabolism* / Q000502:physiology; D004563:Electrochemistry; D008297:Male; D019832:N-Methylscopolamine; D010862:Pilocarpine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012601:Scopolamine / Q000494:pharmacology; D012602:Scopolamine Derivatives / Q000494:pharmacology; D014527:Uric Acid / Q000378:metabolism*
D012602:Scopolamine Derivatives; D010862:Pilocarpine; D014527:Uric Acid; D012601:Scopolamine; D001205:Ascorbic Acid; D019832:N-Methylscopolamine